Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATHFINDER: Optimal First-line Biologics for Ileal-dominant Crohn's Disease
NCT05928039Phase 4Recruiting
- Sponsor
- University of Calgary
- Start
- Oct 2023
- Primary completion
- Jul 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of infliximab, adalimumab, ustekinumab, risankizumab, vedolizumab in Crohn's disease, sponsored by University of Calgary. Started Oct 2023; status: recruiting.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05928039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05928039.